ArticleNutrients2020
Saccharin Supplementation Inhibits Bacterial Growth and Reduces Experimental Colitis in Mice.
Article in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice.Microbiome · 2021Trial
- Common xenobiotics modulate gut microbial responses to low‑calorie sweeteners in vitro.Molecular systems biology · 2026Article
- Metabolomics reveals the hindgut metabolic changes and physiological impacts in weaned piglets subjected to ETEC infection and berberine intervention.Scientific reports · 2025Article
- Nutrition in Inflammatory Bowel Disease: Strategies to Improve Prognosis and New Therapeutic Approaches.Diseases (Basel, Switzerland) · 2025Review
- Saccharin disrupts bacterial cell envelope stability and interferes with DNA replication dynamics.EMBO molecular medicine · 2025Article
- Mendelian randomization analysis reveals causal associations of serum metabolites with sepsis and 28-day mortality.Scientific reports · 2024Article
- The key to intestinal health: a review and perspective on food additives.Frontiers in nutrition · 2024Review
- The Effects of Artificial Sweeteners on Intestinal Nutrient-Sensing Receptors: Dr. Jekyll or Mr. Hyde?Life (Basel, Switzerland) · 2023Review
- Food Additives Associated with Gut Microbiota Alterations in Inflammatory Bowel Disease: Friends or Enemies?Nutrients · 2022Review
- Review
- Ultra-processed foods as a possible culprit for the rising prevalence of inflammatory bowel diseases.Frontiers in medicine · 2022Review
- Non-nutritive sweeteners and their impacts on the gut microbiome and host physiology.Frontiers in nutrition · 2022Review
- Interactions of Non-Nutritive Artificial Sweeteners with the Microbiome in Metabolic Syndrome.Immunometabolism · 2022Article
- Unravelling the Phytochemical Composition and the Pharmacological Properties of an Optimized Extract from the Fruit fromMolecules (Basel, Switzerland) · 2021Article
- Artificial Sweeteners: History and New Concepts on Inflammation.Frontiers in nutrition · 2021Review
- To a Question on the Mechanism of the Antimicrobial Action of Ortho-Benzoic Sulfimide.Pharmaceuticals (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-caloric artificial sweeteners are frequently discussed as components of the "Western diet", negatively modulating intestinal homeostasis. Since the artificial sweetener saccharin is known to depict bacteriostatic and microbiome-modulating properties, we hypothesized oral saccharin intake to influence intestinal inflammation and aimed at delineating its effect on acute and chronic colitis activity in mice. In vitro, different bacterial strains were grown in the presence or absence of saccharin. Mice were supplemented with saccharin before or after induction of acute or chronic colitis using dextran sodium sulfate (DSS) and the extent of colitis was assessed. Ex vivo, intestinal inflammation, fecal bacterial load and composition were studied by immunohistochemistry analyses, quantitative PCR, 16 S RNA PCR or next generation sequencing in samples collected from analyzed mice. In vitro, saccharin inhibited bacterial growth in a species-dependent manner. In vivo, oral saccharin intake reduced fecal bacterial load and altered microbiome composition, while the intestinal barrier was not obviously affected. Of note, DSS-induced colitis activity was significantly improved in mice after therapeutic or prophylactic treatment with saccharin. Together, this study demonstrates that oral saccharin intake decreases intestinal bacteria count and hence encompasses the capacity to reduce acute and chronic colitis activity in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.